Bio Techne (Germany) Today
| TE1 Stock | EUR 72.00 0.50 0.69% |
Performance3 of 100
| Odds Of DistressLess than 9
|
Bio Techne is trading at 72.00 as of the 7th of June 2024. This is a -0.69 percent down since the beginning of the trading day. The stock's lowest day price was 72.0. Bio Techne has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Bio Techne are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2024 and ending today, the 7th of June 2024. Click here to learn more.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. The company has 157.28 M outstanding shares. More on Bio Techne
Moving together with Bio Stock
Moving against Bio Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bio Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bio Techne's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio Techne or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Charles Kummeth |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Bio Techne (TE1) is traded on Frankfurt Exchange in Germany and employs 3,000 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio Techne's market, we take the total number of its shares issued and multiply it by Bio Techne's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bio Techne classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 157.28 M outstanding shares.
Bio Techne has accumulated about 178.79 M in cash with 325.27 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72.
Check Bio Techne Probability Of Bankruptcy
Ownership AllocationBio Techne holds a total of 157.28 Million outstanding shares. The majority of Bio Techne outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Techne to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Techne. Please pay attention to any change in the institutional holdings of Bio Techne as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bio Ownership Details
Bio Techne Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bio Techne market risk premium is the additional return an investor will receive from holding Bio Techne long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bio Techne. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bio Techne's alpha and beta are two of the key measurements used to evaluate Bio Techne's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.74 | |||
| Semi Deviation | 1.58 | |||
| Standard Deviation | 2.82 | |||
| Variance | 7.96 |
Bio Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bio Techne without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Bio Techne Corporate Management
Elected by the shareholders, the Bio Techne's board of directors comprises two types of representatives: Bio Techne inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Techne's management team and ensure that shareholders' interests are well served. Bio Techne's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Techne's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kim Kelderman | Pres Genomics | Profile | |
| David Clair | IR Contact Officer | Profile | |
| Luca Cicchetti | Managing Director | Profile | |
| Brenda JD | Gen VP | Profile | |
| William Geist | Pres Segment | Profile |
Other Information on Investing in Bio Stock
Bio Techne financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Techne security.